Document Type : Original Article
Authors
- Zohreh Babaloo 1, 2, 3
- Reza Khajir Yeganeh 1
- Mehdi Farhoodi 2
- Behzad Baradaran 1, 3
- Mohamadreza Bonyadi 1, 3
- Leila Aghebati 1
1 Department of Immunology, Faculty of Medicine
2 Neuroscience Research Center
3 Immunology Unit, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Background: Effector CD4+ T cell subsets play an important role in Multiple Sclerosis (MS). Interleukin-27 (IL-27) suppresses Th (Th1, Th2 and Th17) cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells (Tr1).
Objective: To identify the relative levels of IL-27 and IL-17A in MS disease.
Method: In a case-control study, venous blood was collected from forty MS patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL-17A were measured by ELISA method.
Results: A significant difference between serum IL-17A concentration in patients (120.68 ± 209.85 pg/ml) and control group (67.26 ± 117.76 pg/ml, p=0.016) was found. Serum IL-27 levels of the MS patients (159.7 ± 581.4 pg/ml) were significantly lower than control subjects (180.35 ± 507.84 pg/ml, p=0.001).
Conclusion: Our findings show decreased levels of IL-27 against increasing IL-17A levels in patients group which may suggest the suppressive role of IL-27 on inflammatory process of MS.
Keywords
)